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Background: Women with depression in pregnancy are faced with difficult treatment decisions. Untreated, antenatal
depression has serious negative implications for mothers and children. While antidepressant drug treatment is likely to
improve depressive symptoms, it crosses the placenta and may pose risks to the unborn child. Transcranial direct
current stimulation is a focal brain stimulation treatment that improves depressive symptoms within 3 weeks of
treatment by inducing changes to brain areas involved in depression, without impacting any other brain areas, and
without inducing changes to heart rate, blood pressure or core body temperature. The localized nature of transcranial
direct current stimulation makes it an ideal therapeutic approach for treating depression during pregnancy, although it
has never previously been evaluated in this population.
Methods/design: We describe a pilot randomized controlled trial of transcranial direct current stimulation among
women with depression in pregnancy to assess the feasibility of a larger, multicentre efficacy study. Women over
18 years of age and between 14 and 32 weeks gestation can be enrolled in the study provided they meet diagnostic
criteria for a major depressive episode of at least moderate severity and have been offered but refused antidepressant
medication. Participants are randomized to receive active transcranial direct current stimulation or a sham condition
that is administered in 15 30-minute treatments over three weeks. Women sit upright during treatment and receive
obstetrical monitoring prior to, during and after each treatment session. Depressive symptoms, treatment acceptability,
and pregnancy outcomes are assessed at baseline (prior to randomization), at the end of each treatment week, every
four weeks post-treatment until delivery, and at 4 and 12 weeks postpartum.
Discussion: Transcranial direct current stimulation is a novel therapeutic option for treating depression during
pregnancy. This protocol allows for assessment of the feasibility of, acceptability of and adherence with a clinical trial
protocol to administer this treatment to pregnant women with moderate to severe depression. Results from this pilot
study will guide the development of a larger multicentre trial to definitively test the efficacy and safety of transcranial
direct current stimulation for pregnant women with depression.
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Depression is the second leading cause of disability in
women and is the most common morbidity in pregnancy
[1,2]. Left untreated, in-utero exposure to depression can
lead to serious impacts on the child, including preterm
birth, reduced birth weight, small head circumference
and lower Apgar scores during the neonatal phase, and
increased risk of poor developmental and emotional out-
comes, including higher risk of both internalizing (for
example, anxiety) and externalizing (for example, atten-
tion deficit hyperactivity disorder) disorders in childhood
[3,4]. Given the high prevalence and substantial impact
on children, rapid, effect treatment of depression during
pregnancy is a high priority.
Unfortunately, no existing treatment option for depres-
sion in pregnancy is without potential risk. There are two
standard types of treatment for depression in pregnancy:
(1) psychotherapy and (2) antidepressant medication. Mild
depression during pregnancy can be treated with psycho-
therapy, but this is unlikely to result in substantive im-
provements if a woman has moderate to severe depression
(effect sizes ranging from 0.15 for interpersonal therapy to
0.39 for cognitive behavioural therapy) [5]. It may also take
several weeks to months to improve depressive symptoms,
leaving the mother and fetus exposed to the effects of un-
treated (or incompletely treated) depression during that
time. Antidepressant medication is an effective treatment
option (effect size approximately 0.61 for selective sero-
tonin reuptake inhibitors compared with placebo) and
is the recommended first line of treatment for major de-
pression in pregnancy [5,6]. However, concerns about the
safety of antidepressant medication exposure for the de-
veloping fetus limit its acceptability among patients and
providers. Its use has been associated with small absolute
risk increases of neonatal cardiovascular malformations
and neonatal pulmonary hypertension, as well as reports
of spontaneous abortion, low birth weight, preterm birth,
fetal death and seizures among exposed infants [7-21].
Antidepressant medication also crosses the placenta and
uncertainty remains about whether there are any long-
term negative effects on the child [22].
Transcranial direct current stimulation (tDCS) is a
novel brain stimulation technique that has the potential
to be an ideal treatment option for depression in preg-
nancy. It is a localized brain stimulation treatment that
is based on an understanding that there are abnormal-
ities in activity in frontal brain regions in this disorder,
particularly the left and right dorsolateral prefrontal cor-
tices [23-26]. This technique involves the application of
a small current (1 to 2 mA) between two electrodes
placed on the scalp that induces localized neuronal ac-
tivity in the prefrontal cortex [27,28]. A meta-analysis of
ten studies reported that compared with sham tDCS, ac-
tive tDCS was more effective in reducing symptoms ofdepression after 2 to 3 weeks of treatment [29]. A recent
large, randomized sham-controlled trial confirmed these
findings with an effect size on depression outcome of
0.49 [30]. Importantly, tDCS has been shown to be safe
in a number of trials [31-37]. Worldwide, no major ad-
verse events have been reported in 2,000 to 3,000 known
human subjects [38]. The procedure produces a mild
tingling sensation initially, which usually resolves within
30 seconds. In a study examining the side effects of 567
sessions of tDCS with 77 healthy controls and 25 patients,
the most common side effects of tDCS were a mild
tingling sensation, moderate fatigue and a light itching
sensation under the stimulation electrodes. After tDCS,
headache (10%), nausea (<3%) and insomnia (<1%) have
been reported [39]. Relevant to the application of this
method in pregnant women, a recent brain imaging study
demonstrated that tDCS can produce changes in regional
brain activity in the prefrontal cortex without inducing
changes in any other brain area [28]. Furthermore, another
recent tDCS study found no changes in autonomic func-
tion, ventilation rate or core body temperature attributable
to tDCS applied in healthy volunteers [40]. Thus, the lo-
calized stimulation presents no theoretical risk to the
fetus. Furthermore, it is an accessible treatment option.
The equipment required is inexpensive and portable and
can be administered by trained technicians or by patients
themselves at home once the stimulation parameters are
appropriately programmed.
In summary, tDCS is a novel technique with strong
promise to allow women presenting with depression
during pregnancy a safe, nonpharmacological treatment.
Herein we present the methodology of a pilot random-
ized controlled study that evaluates the feasibility of a
trial protocol for tDCS in pregnant women with depres-
sion (research protocol version 3; 10 April 2014). The
primary objective of this protocol is to assess feasibility,
acceptability and adherence with a prospective, two-
armed, sham-controlled, pilot randomized controlled
trial (RCT) protocol to evaluate tDCS for the treatment
of depression in pregnant women. This will guide the
development of a larger multisite RCT to definitively
evaluate the efficacy of tDCS treatment for depression
during pregnancy. The secondary objective of the pilot
study is to measure the effect of tDCS on reducing de-
pressive symptoms immediately post-treatment among
women who have moderate to severe depression in preg-
nancy. This will generate a preliminary effect size to in-
form the sample size required for a more definitive RCT.
Methods/design
Study design, setting and recruitment
This is a two-armed, sham-controlled, pilot RCT (see
Figure 1). The pilot RCT is recruiting women with de-
pression in pregnancy over the course of 1 to 2 years
Figure 1 Trial design. Randomization schema of a pilot randomized
controlled trial on the feasibility of transcranial direct current
stimulation to treat depression during pregnancy. MADRS,
Montgomery Asberg Depression Rating Scale; tDCS, transcranial
direct brain stimulation.
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Departments of Psychiatry and Obstetrics and Gynecology
at two university-affiliated hospitals in Toronto, Ontario,
Canada (Mount Sinai Hospital and Women’s College
Hospital). Both hospitals receive referrals for mental health
care of women during pregnancy from all over the Greater
Toronto Area (population ≈ 3.5 million). To help achieve
adequate participant enrolment, flyers have been placed at
the recruitment sites, and physicians providing antenatal
care at both sites have been informed of the study to assist
with identification of potentially eligible participants.
Physician education about the study has included small and
large group presentations, as well as an information sheet.
Both the intervention and sham control are delivered in the
Clinical Research Unit at Mount Sinai Hospital by trained
obstetrical research nurses to ensure appropriate obstetrical
monitoring during the procedures. The active phase of the
study involves a total of 15 sessions of the intervention or
sham control lasting 30 minutes each over approximately
3 weeks (one per weekday). Participants are then followed
through the remainder of the pregnancy, and until 12 weeks
postpartum with outcome data collected by Masters-level
trained research staff. Outcome data collectors, participants
and physicians providing clinical care are blind to study
group allocation. The study was approved by the researchethics boards of Women’s College Hospital (Reference
Number 2013-0085-B) and Mount Sinai Hospital (Reference
Number 13-0320-A) in Toronto, Ontario. The study is
registered with ClinicalTrials.Gov under the identifier
NCT02116127. The research ethics boards of both institu-
tions involved in the study are notified if any changes are
made to the study protocol. The trial registration is also
updated as appropriate.
Eligibility criteria
To be included in the study, women must: (1) be pregnant
and aged at least 18 years; (2) be >14 weeks and ≤32 weeks
of gestation at enrolment; (3) meet diagnostic criteria for
major depressive disorder, with a current major depressive
episode of at least moderate severity (according to version
5 of the Diagnostic and Statistical Manual of Mental Dis-
orders, DSM-5) confirmed by an assessment with the Mini
International Neuropsychiatric Interview [41]; (4) have
been offered, but declined to use, antidepressant medica-
tion by their treating clinician at one of the two recruit-
ment sites; (5) be assessed by the principal investigator
to be eligible for outpatient psychiatric treatment; and
(6) be capable of consenting to treatment and understand-
ing study explanations and questionnaires in English.
Our sample is restricted to women between 14 and
32 weeks gestation to increase the likelihood that partici-
pants remain pregnant through the active phase of the
study (that is, women in the first trimester of pregnancy
have a greater chance of spontaneous abortion) [42];
women >32 weeks gestation would have a higher likeli-
hood of delivery during the intervention phase, especially
given that women with depressive symptoms have an
increased risk of late preterm births [43]. We are only en-
rolling women who have been offered, but declined, treat-
ment with antidepressant drugs because this treatment,
despite its potential disadvantages, remains the standard
of care in this population [5]. Participants are excluded
from the study if they: (1) have a DSM-5 diagnosis of alco-
hol or substance use or dependence in the previous six
months; (2) have concomitant major and unstable medical
or neurological illness or history of seizure; (3) are cur-
rently taking carbamazepine (as this may reduce the
efficacy of tDCS treatment); (4) are currently taking benzo-
diazepines on a daily basis (not including intermittent use
of lorazepam of <2 mg per day); (5) have metal implants in
the cranium, electrical implants in the body, or nonintact
skin on the scalp areas where stimulation electrodes will be
placed (as per tDCS device manufacturer specifications);
(6) have major obstetrical complications or a known fetal
anomaly during the current pregnancy as determined by
the investigator team; (7) have a history of very preterm
(that is <32 weeks gestation) delivery for a previous preg-
nancy; or (8) are planning to leave the study city prior to
delivery during the current pregnancy.
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Potentially eligible women who are willing to hear more
about the study receive a detailed study explanation
from the study research coordinator. Subjects are pro-
vided with a clear explanation of the objectives, proce-
dures, risks and benefits of the study and all questions
are answered. Questions are asked of subjects to ensure
that they understand the nature of the research, risks
and potential benefits of study participation, and their
rights as research subjects prior to their signing the in-
formed consent document. Interested patients are asked
to sign the informed consent form before entry into the
study. Informed consent is obtained before any study as-
sessments and study procedures are performed and be-
fore any private information is recorded. Participants are
given meaningful opportunities during the study to pro-
vide ongoing consent to continuation with the study
protocol. Among pregnant women who are faced with
treatment decisions, it has been shown that the opinions
of partners, and even family and friends can play a large
role [44]. We routinely request that a woman invite her
partner to be present for the initial discussions about the
study, so that all of the individuals involved in the deci-
sion about whether or not to enrol in the study have ad-
equate information about it.
Allocation of interventions
After informed consent procedures and collection of base-
line data, eligible and consenting women are randomized
to receive either the active tDCS intervention or a sham
control condition. A research assistant external to the
study generated the allocation sequence using a random
permuted block randomization table. Randomization
identification numbers (RIDs) in the table are stratified
based on gestational age at enrolment, to increase the like-
lihood that groups will be balanced with respect to gesta-
tional age at entry. As such, the first stratum of RIDs is
assigned to participants who are less than 24 weeks preg-
nant at enrolment. The second stratum of RIDs is assigned
to participants who are 24 or more weeks pregnant at en-
rolment. The group allocations were placed in sealed en-
velopes with RIDs written on the front by the external
research assistant. The study research coordinator assigns
RIDs sequentially, then selects a presealed envelope with
the RID written on the front to include in the participant’s
research chart. At the time of the session, the obstetrical
research nurse who administers the tDCS intervention or
sham opens the envelope to determine the group alloca-
tion. It is necessary for the research nurse to know the
group allocation because the tDCS device must be pro-
grammed differently depending on whether the participant
is to receive the active tDCS intervention or control. The
research nurse does not provide clinical care nor collect
outcome data.Interventions
A total of 15 sessions lasting 30 minutes each are ad-
ministered to participants over approximately 3 weeks
(one per weekday) by a trained obstetrical research nurse
at the hospital. Training in the administration of active
tDCS and sham procedures was provided by DB (the co-
principal investigator) who has experience in training
tDCS technicians and has conducted previous tDCS
treatment trials using trained technicians to administer
the intervention [45-47]. Participants are awake and sit
as upright as possible during treatment. The tDCS ob-
stetrical research nurse who administers the intervention
measures maternal blood pressure and heart rate prior
to the procedure. Participants receive continuous fetal
monitoring for 10 minutes prior to the tDCS or sham
stimulation, for the duration of the session and for
10 minutes afterward using a nonstress test. For partici-
pants who are too early in their pregnancy to receive
continuous fetal monitoring (that is, prior to 24 weeks
gestation), a fetal heart rate measurement is recorded
10 minutes before and after each session. Maternal blood
pressure and heart rate are recorded after each session for
all participants. The active tDCS intervention and sham
protocols are based on those provided to nonpregnant re-
search participants in the investigators’ previous tDCS tri-
als [45-47]. The active tDCS intervention is active 2 mA
tDCS. Direct current is transferred continuously for 30
minutes with a pair of saline-soaked sponge electrodes
(contact area of 5 × 7 cm), and delivered by a specially
developed, battery-driven constant current stimulator.
The electrodes are placed over F3 and F4 according to the
10–20 international system for electroencephalogram
placement. This has been shown to be a relatively accurate
method of dorsolateral prefrontal cortex localization by
neuronavigation methods [48]. It has been used before in
tDCS studies targeting the dorsolateral prefrontal cortex
(an important area implicated in the etiology of depres-
sion) and has demonstrated efficacy in treatment studies
of resistant depression [34,35,47]. The control or ‘sham’
stimulation is administered using the same stimulation pa-
rameters and at the site of active treatment, but the
current is turned off after 30 seconds. Typically, tDCS in-
duces an itching or tingling sensation for the first 30 sec-
onds of its application, which then fades, making this an
appropriate blinding method. During the sessions them-
selves, the obstetrical research nurses have been instructed
to limit engagement with participants, in order to prevent
co-intervention and to prevent accidental unblinding of
participants during the session.
Women continue to receive clinical care from their re-
spective clinical programmes during the trial, however,
their clinical care providers are blind to their group alloca-
tion. Although this care may include psychotherapeutic
intervention that is initiated prior to completion of the
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waiting list is short), significant improvement within the
first 3 weeks of psychotherapeutic treatment is unlikely. As
such, this is an ideal opportunity to evaluate the efficacy of
a new treatment, without depriving women of nonpharma-
cological standard care. For ethical reasons, clinical care
might include offering of antidepressant medication as in-
dicated because, despite its risks, antidepressant medica-
tion remains the standard of care for moderate to severe
depression. If a participant begins antidepressant medica-
tion during the course of the study, this will be docu-
mented but the participant will remain in the study.
Specific criteria for termination of participation are active
suicidal ideation, psychosis, treatment-emergent mania and
acute pregnancy complications during and after treatment
(as determined by the study team). If any termination cri-
teria are met, the participant will end all sessions, inde-
pendent of group allocation, and be followed-up by her
physician. Participants who terminate early will be included
in the intention-to-treat analysis, and we will continue to
collect follow-up data if participants are willing.
Study schedule
The study schedule is described in Table 1. A baseline visit
with the research coordinator (blind to group allocation)
occurs in person, prior to the start of the active study phase
to collect baseline demographic and health service use in-
formation, and to collect baseline measures on mental
health symptom scales. During the active study phase, study
session visits are daily on weekdays over 3 weeks when par-
ticipants are receiving either the tDCS intervention or the
sham treatment. The obstetrical research nurse administer-
ing the session records information on each visit, including
maternal and fetal heart rate, maternal blood pressure, start
and stop time of active or sham tDCS, and any interrup-
tions, using a session log. In addition, active study phase in-
terviews are conducted in person with the research
coordinator following the final session each week. Follow-
up questionnaires are then completed in person or by tele-
phone (depending on patients’ preferences) every 4 weeks
until delivery, and at 4 and 12 weeks postpartum. Several
post-recruitment retention strategies are used to retain par-
ticipants in this study and optimize follow-up data collec-
tion rates. First, women receive transit tokens or parking
reimbursement as required. Second, subsequent to the ac-
tive study phase, women are contacted by telephone and
email to remind them about their follow-up assessments.
Women also receive email updates about recruitment tar-
gets and follow-up completeness to help them understand
the contribution they are making by remaining in the study.
Outcomes
The primary outcome measures for the pilot study are (1)
feasibility, (2) acceptability and (3) adherence with the trialprotocol. Feasibility describes how well the trial protocol
can be implemented. We record feasibility data related to
(a) eligibility (for example, proportion of reproductive
mental health clinic patients eligible), (b) recruitment (for
example, number, nonparticipation reasons) and (c) timing
(for example, time before participant begins treatment).
We also assess the feasibility of our blinding methods
by asking women whether they believe they are receiv-
ing active or sham stimulation at the end of each week
of the active study phase. Acceptability refers to women’s
satisfaction with and perceptions of the intervention
and what side effects or adverse outcomes (if any) are ex-
perienced. To demonstrate acceptability, a focus on fetal,
maternal, neonatal and child outcomes is essential. Ac-
ceptability measures are: (a) fetal monitoring during each
session (as described above); (b) the Toronto Side Effects
Scale at the end of each week of the active study phase
[49]; (c) a semistructured treatment perceptions interview
at the end of the intervention phase; and (d) question-
naires to assess additional maternal, neonatal infant and
child outcomes. We do not expect any specific maternal
or neonatal complications to occur as a result of this
protocol. Therefore, questionnaires to assess maternal and
neonatal outcomes ask specifically about the perinatal
health indicators recommended by the Canadian Perinatal
Surveillance System [50]. These questionnaires are admin-
istered at the end of each week of the active study phase,
and at each follow-up visit until the 4-week postpartum
visit. To increase accuracy of the self-report measures for
these perinatal health indicators, we provide participants
with a copy of the relevant questionnaires. We also re-
quest that women allow us to obtain their infant outcome
data from their clinical records to validate the self-report
data against that for the pilot. For early childhood out-
comes, temperament is assessed using the Infant Charac-
teristics Questionnaire, an instrument that uses a series of
similarly constructed questionnaires developed to assess
parental perceptions of difficult infant temperament [51];
and infant development is assessed using the Ages and
Stages Questionnaire, a 30-item instrument that uses a
series of similarly constructed questionnaires to screen
child development from 1 through 60 months of age
[52,53]. Finally, we assess adherence, defined as the degree
to which the trial protocol is followed. Adherence-related
measures include (a) the number of women who complete
the 15 active study phase sessions and reasons for discon-
tinuation, (b) the total number of sessions attended over-
all, and within the intended active study phase (that is,
3 weeks) and (c) the rate of follow-up data collection.
Follow-up data collection is especially important because
ideally, in the large multicentre trial, we would like to be
able to obtain detailed measures of neonatal health in the
postpartum period and follow children longitudinally to
measure child outcomes.




Prior to active study phase Active study phase Follow-up









Eligibility screen X Feasibility
Informed consent X Feasibility
Group allocation X Feasibility
Demographic questionnaire X Covariates
Mini International Neuropsychiatric Interview X Covariates
Health service use questionnaire X X X X X X X Covariates
Montgomery Asberg Depression Rating Scale X X X X X X X Adherence, efficacy
Edinburgh Postnatal Depression Scale X X X X X X X Adherence, efficacy
Pregnancy Experience Scale X X X X X X X Adherence, efficacy
State-Trait Anxiety Inventory X X X X X X X Adherence, efficacy
Pregnancy complications X X X X X X Acceptability, adherence
Fetal monitoring X Acceptability, adherence
Treatment allocation questionnaire X X X Feasibility
Toronto Side Effects Questionnaire X X X Acceptability, adherence
Treatment perceptions interview X Acceptability, adherence
Neonatal outcomes X Acceptability, adherence
Infant characteristics questionnaire X Acceptability, adherence
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tionnaires administered by the research coordinator at
baseline, weekly during treatment, immediately post-
treatment at the end of the active study phase (primary
efficacy measure), at 4-week intervals until delivery, then
at 4 and 12 weeks postpartum, to obtain information
about the duration of response subsequent to active
study phase (that is, how long any observed response is
sustained). The main secondary outcome measure for
the study is the level of depressive symptoms immedi-
ately post-treatment. This outcome is measured using
the 10-item Montgomery Asberg Depression Rating
Scale (MADRS), a standard clinician-administered meas-
ure of depressive symptoms with good reliability (Cron-
bach alpha, 0.85) and validity (coefficient, 0.314) in
clinical populations [54,55]. The MADRS has good re-
sponsiveness to the effect of antidepressant treatments
and has been used in previous tDCS trials. The items
are rated on a seven-point (0 to 6) scale (score range 0
to 60). To generate preliminary efficacy data that can be
used to inform sample size calculations of the subse-
quent treatment trial, we will compare MADRS scores
immediately after the active study phase between tDCS
intervention and sham comparison groups, accounting
for baseline MADRS scores in the analyses. We also
measure depressive symptoms using the Edinburgh Post-
natal Depression Scale (EPDS), a self-report depression
screening measure that has been validated for use in
pregnancy with a pooled internal consistency of 0.73 to
0.87 and test-retest reliability of 0.53 to 0.74 [56,57].
Women with EPDS scores greater than 12 have ten
times the likelihood of having diagnosis of major depres-
sive disorder than women with EPDS less than 12 [58].
Although the scale itself is not diagnostic of major de-
pressive disorder and is not traditionally used as a pri-
mary outcome measure in depression treatment studies,
it has a better ability to detect women with depression
in the perinatal period than traditional depression mea-
sures because of the increased weight given to anxiety
symptoms that appear to be more common in perinatal
than in nonperinatal depression. Additional maternal
symptom measurements include the Pregnancy Experi-
ence Scale, as this has been validated against physio-
logical measures in the developing fetus [59]. We will
measure anxious symptoms using the State-Trait Anx-
iety Inventory, a self-report anxiety screening measure
that has shown good discriminative validity in perinatal
populations for the identification of anxiety disorders
[60]. We also inquire about concurrent psychosocial or
psychiatric health services to which participants may
have been exposed (for example, psychotherapy, public
health nursing, postpartum antidepressant use) as these
exposures have the potential to confound treatment or
safety effects if unbalanced between groups (see Table 1).Statistical methods
We will use descriptive methods to estimate feasibility
and compliance for the number of tDCS intervention
and sham sessions, the length of time each session
lasted, follow-up rates at the various intervals, recruit-
ment rate, rates of nonparticipation, and so on. We will
calculate acceptability using Likert-type scale responses
of the mothers’ satisfaction with the procedure and
reported side effects, pregnancy, neonatal and child out-
comes. Quantitative continuous measures will be com-
pared between intervention and sham groups using
t tests for normally distributed continuous variables,
using chi-square tests of association for quantitative di-
chotomous measures or other nonparametric tests where
appropriate. To compare depressive symptoms between
depressed women receiving the tDCS intervention to de-
pressed women receiving the control after 3 weeks of
treatment analyses, we will use the intention-to-treat
principle. Missing data points will be excluded from the
analysis, and individuals with fewer than two depression
measurements will be treated as lost to follow-up. An on-
treatment analysis will also be performed as a sensitivity
analysis (to determine the best possible performance of
tDCS). Means of the MADRS scores of the intervention
and control groups at the primary endpoint will be com-
pared using a one-way analysis of covariance (ANCOVA)
model, where the covariate will be the baseline MADRS
score. This effect size will be used to generate the sample
size needed for the future multicentre trial.
Sample size
A review by Hertzog suggests a range of 20 to 40 partici-
pants to allow for sufficient variability in acceptability
assessment of an intervention [61]. The referral sites re-
ceive approximately 100 referrals per month for ante-
natal depression combined, with approximately 20 being
for moderate to severe depression in pregnancy. Based
on recruitment for a previous study focused on women
faced with decisions regarding antidepressant drug use
in pregnancy [62], we estimate that ten patients (50%)
will be ineligible because they accept antidepressant drug
treatment, that four will be ineligible for other reasons
and that three of the remaining six (50%) will consent to
participate in the pilot study. Therefore, recruitment of
36 women could be achieved within 1 year. For women
in the moderate depression range (that is, with a MADRS
score of 16), this would allow us to detect a 30% difference
in depressive symptom scores (clinically significant) be-
tween intervention and control participants with a prob-
ability (power) of 0.9 (alpha = 0.05).
Safety monitoring
The study investigator team is well-positioned to assess
and monitor safety in this pilot study given its collective
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and obstetrics and gynecology. Safety and adverse events
are assessed daily during the active phase and at all
follow-up time points and are routinely reviewed by the
principal investigator. An obstetrician co-investigator
(blind to group allocation), reviews all fetal heart rate
tracings after all routine tDCS and sham sessions, and is
available (or has support) should any concerns arise dur-
ing the sessions themselves. Urgent psychiatric issues of
concern expressed to the obstetrical research nurse or
the research coordinator would be: suicidal ideation,
homicidal ideation, concern over harm to children or
evidence of psychotic symptoms, or could include any
other psychiatric concerns as per the judgement of
the obstetrical research nurse or research coordinator.
Urgent medical concerns expressed to the obstetrical re-
search nurse or research coordinator would be consid-
ered to be any acute medical symptoms reported by the
patient or observed by the study staff, as well as any
concerns about fetal wellbeing expressed by the patient.
In this case, the obstetrical research nurse or research
coordinator would stop the session (if this occurs during
treatment), keep the participant in the office (or on the
telephone) and contact the study’s principal investigator
(psychiatrist) for direction. The study’s principal investi-
gator would assess the patient immediately, with input
from the study obstetricians and maternal-fetal medicine
specialists, as required. If no urgent medical or psychi-
atric concerns are identified based on this clinical assess-
ment, the participant is directed back to her psychiatric
or antenatal care provider. If necessary, the participant is
directed to emergency services. If contact with partici-
pant is lost prior to assessment (that is, if adverse events
are reported by telephone), then emergency services are
contacted. Adverse events are recorded and immediately
reported (within 24 hours by telephone or fax) to the
research ethics boards of both institutions for consider-
ation of further action (that is, unblinding of interven-
tion, subject withdrawal, termination of study). Participants
receive care as appropriate for any harm that arises as a re-
sult of study participation.
Dissemination plan
The nature of this research is to determine whether it is
feasible to conduct a large multisite RCT to evaluate the
treatment effect of tDCS, a novel nondrug approach in
women with moderate to severe depression in preg-
nancy. As such, the goals of the dissemination plan rele-
vant to this pilot study are to: (1) inform future research
in terms of providing evidence to proceed to a larger
multicentre study of the efficacy of tDCS in treating
pregnant women with depression; and (2) generate
awareness and interest in both the research community
and in the public about the potential of this treatmentfor preventing adverse child and maternal outcomes.
This is highly important at this early stage in develop-
ment, because once efficacy and safety are established,
the long-term dissemination plan will be to generate ac-
tion in practice change, promoting broad treatment up-
take. With such low acceptability rates for treatment
of depression in pregnancy, it is essential to involve
practitioners and stakeholders throughout the initiation,
conduct and outcome stages. This will help confront
barriers to treatment acceptability (among patients and
practitioners) by ensuring that clear, unbiased informa-
tion is passed to potential treatment users so that they
can make effective and timely decisions about treatment.
To meet the first goal of this dissemination plan, poten-
tial partners for the planned multicentre trial require en-
gagement. Our multidisciplinary team has connections
with centres where women are treated for depression in
pregnancy throughout Canada, the United States and
internationally. Our team also has connections with clin-
ical brain stimulation programmes at many of these
sites, and can provide training in the use of the tDCS
procedure. To meet the second goal of the dissemination
plan, practitioners, the public, stakeholder groups and
policy makers are target audiences. To engage our part-
ners in the design and development of the multicentre
trial, we will hold a trial planning meeting in the last
stages of the current project (as long as our criteria for
feasibility are met). We will also present the results of
the pilot study in at least one national and one inter-
national conference in psychiatry or brain stimulation
and submit results for peer-reviewed publication to pro-
mote the legitimacy of our findings. To communicate
the findings to the broader community of providers, pol-
icy makers, women and their families in an encouraging
and nonstigmatized manner, so that we can promote
interest in participation in the larger treatment trial and
later uptake of this treatment method, we will focus on
generating awareness of the results of the pilot trial. We
will disseminate the findings of our pilot study (after
peer review) through our hospital websites and to our
community stakeholders through small group presenta-
tions to the stakeholders at each of these agencies. We
consider these presentations to be integrated knowledge
transfer as they will be bidirectional in nature; they will
help to inform us about patient needs and perceptions,
while at the same time serving as mechanisms to dis-
seminate information and generate interest and aware-
ness of the potential of tDCS treatment.
Discussion
Depression complicates up to 10% of pregnancies, more
than gestational diabetes, hypertension or pre-eclampsia
[1]. No standard treatment option comes without poten-
tial risks for mother or fetus. Transcranial direct current
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ment of depression during pregnancy. It has the poten-
tial to introduce a safe, effective, low-cost and accessible
method for treatment of depression during pregnancy.
The protocol described in this paper is a pilot RCT de-
signed to guide the development of a larger multicentre
study to definitively determine the safety and efficacy of
tDCS as a treatment option for depression during
pregnancy.
The strengths of our protocol include: (1) the use of a
novel treatment option for depression during pregnancy
that has not been previously described in this popula-
tion; (2) robust fetal monitoring methods, to ensure the
safety of both the mother and the unborn child, as well
as to provide reassurance to the mother during treat-
ment sessions; (3) extensive follow-up, to monitor the
progress of the pregnancy, depressive symptoms and
other health service use indicators that may influence
outcomes; (4) study oversight by a strong team with a
diverse range of expertise and training in the fields of
reproductive and perinatal mental health, brain stimula-
tion, obstetrical medicine and developmental neurosci-
ence; and (5) a comprehensive dissemination plan to
ensure adequate uptake of the knowledge that this study
will generate. There are some limitations to the pilot
study methodology, however. First, recruitment is lim-
ited to women seen at our specialty perinatal mental
health clinics, and thus the recruitment and retention
rates may not be applicable to centres with more general
psychiatric or general obstetrical populations. That being
said, our centres are likely to have the highest propor-
tion of potentially eligible patients, making this an ideal
setting for a pilot study. Second, we restricted our sam-
ple to women between 14 and 32 weeks gestation to in-
crease the likelihood that women in our small planned
sample would remain pregnant through active treatment.
The disadvantage of this is that our study results are not
necessarily applicable to women in early or late preg-
nancy, and that this will need to be addressed in future
research. Finally, because this is a pilot study, our results
will not support definitive conclusions on efficacy or
safety of tDCS during pregnancy. In fact, they will help
guide the development of a larger study to focus on
these outcomes.
Some of the challenges of developing this protocol and
the creative solutions to these challenges are worthy of
discussion. Research has demonstrated that pregnant
women are very hesitant to undergo any medical treat-
ment during pregnancy (and providers are often reluc-
tant to recommend treatments), out of concern for
the safety of the fetus. Although tDCS represents no the-
oretical risk to the fetus, it has not been evaluated in
pregnant patients. Therefore, we anticipated our main
challenges to be with recruitment. To assist with this,we focused on both participants and providers. To assist
patients in decision making, we allowed for the inclusion
of partners in the informed consent process. Our rigor-
ous fetal monitoring protocols were put in place not
only to provide safety data relevant to the study, but also
to provide reassurance to participants over the safety of
the fetus during the procedure itself, possibly increasing
the likelihood of participation. To engage providers, we
presented on depression in pregnancy and on tDCS spe-
cifically to both the mental health and obstetrical depart-
ments in the respective institutions to ensure that a wide
range of providers seeing these patients had a good un-
derstanding of the reasons for treating depression and of
the proposed treatment with tDCS. These presentations
led us to develop, at the suggestion of the practitioners,
an information sheet for practitioners that could help
guide their discussions. These interactive multidisciplin-
ary presentations helped us to develop the content
of the information sheets. For example, obstetrical pro-
viders indicated that their comfort with the tDCS proce-
dures was increased when they considered the similarities
to transcutaneous electrical nerve stimulation (TENS), a
procedure used to relieve pain during labour and delivery.
The strength of the TENS current is approximately
100 mA (50 to 100× the strength of tDCS), it is delivered
directly to the abdomen, and many years of data indicate
that it can be applied in pregnant populations with no ill
effects [63]. We anticipate that education and support of
the providers will aid in comfort of patients considering
participation in the study.
In summary, this protocol was developed through
strong collaborations between psychiatric and obstetrical
service delivery providers and research practices. This
includes recognition that provision of appropriate men-
tal health care requires dialogue between all providers
and care systems involved, particularly during vulnerable
periods of time, such as during a pregnancy. This pilot
RCT will allow us to assess the feasibility of a trial
protocol for administering tDCS among pregnant
women with moderate to severe depression. It will help
guide the development of a larger, multicentre RCT to
assess tDCS in this population that is in great need of a
safe and effective treatment for depression.Trial status
Enrolment for this study began on 2 July 2014. At the
time of submission, we have enrolled 0 participants.Abbreviations
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current stimulation; TENS: transcutaneous electrical nerve stimulation.
Vigod et al. Trials 2014, 15:366 Page 10 of 11
http://www.trialsjournal.com/content/15/1/366Competing interests
DB receives research support from the Canadian Institutes of Health
Research, Brain and Behavior Research Foundation (formerly NARSAD),
National Institutes of Health, Temerty Family through the Centre for
Addiction and Mental Health Foundation and the Campbell Family Research
Institute. He receives nonsalary operating funds and in-kind equipment
support from Brainsway Ltd. for an investigator-initiated study. He is the site
principal investigator for a sponsor-initiated clinical trial from Brainsway Ltd.
He receives in-kind equipment support from Tonika/Magventure for an
investigator-initiated study. In the last 5 years, ZD received research and
equipment in-kind support for an investigator-initiated study through
Brainsway Inc. ZD has also served on the advisory board for Hoffmann-La
Roche Limited and Merck and received speaker support from Eli Lilly. The
other authors do not have any competing interests, financial or otherwise, to
disclose. The founder of the study did not have any role in the study design,
in the plan for the collection, management and analysis of data, in the
writing of this paper, or in the decision to submit this paper for publication.
Authors’ contributions
SV is the primary investigator of the study and developed the study design
and trial schema. She drafted the manuscript, edited it and approved the
final version for publication. CLD, ZD, KM, JR and TO contributed to the
development of the study design and trial schema, edited the manuscript
and approved the final version for publication. SS was a former research
coordinator and contributed to the development of the study design and
trial schema. She edited the manuscript and approved the final version for
publication. NH-S is the current research coordinator and contributed to the
development of the study design and trial schema. She assisted with drafting
the manuscript, edited the manuscript and approved the final version for
publication. DB is the senior investigator of the study and developed the
study design and trial schema. He contributed to the drafting and editing of
the manuscript and approved the final version for publication.
Acknowledgements
We would like to acknowledge the contributions of Mary-Jean Martin, Sheryl
Hewko, Kim Foshay, Cheryl Brush, Maria Rocco from Mount Sinai Hospital in
Toronto, Ontario who are the obstetrical research nurses that administer the
tDCS intervention and sham control. They reviewed the study protocol in
depth and made suggestions for modification to ensure successful
implementation.
Funding for this study was provided by the SickKids Foundation and the
Canadian Institutes of Health Research Institute for Child and Youth Health
and Development.
Author details
1Women’s College Hospital and Research Institute, 76 Grenville Street,
Toronto, ON M5S 1B1, Canada. 2University of Toronto, 563 Spadina Crescent,
Toronto, ON M5S 2 J7, Canada. 3Centre for Addiction and Mental Health, 250
College Street, Toronto, ON M5T 1R8, Canada. 4Mount Sinai Hospital, 600
University Avenue, Toronto, ON M5G 1X5, Canada. 5St Michael’s Hospital, 30
Bond Street, Toronto, ON M5B 1 W8, Canada. 6University of British Columbia,
2329 West Mall, Vancouver, BC V6T 1Z4, Canada.
Received: 3 July 2014 Accepted: 10 September 2014
Published: 18 September 2014
References
1. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR: Prevalence of
depression during pregnancy: systematic review. Obstet Gynecol 2004,
103(4):698–709.
2. Michaud CM, Murray CJ, Bloom BR: Burden of disease - implications for
future research. JAMA 2001, 285(5):535–539.
3. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF,
Perel JM, Jones-Ivy S, Bodnar LM, Singer LT: Major depression and
antidepressant treatment: impact on pregnancy and neonatal outcomes.
Am J Psychiatry 2009, 166(5):557–566.
4. Marcus SM: Depression during pregnancy: rates, risks and consequences -
Motherisk update 2008. Can J Clin Pharmacol 2009, 16(1):e15–e22.
5. Canadian Psychiatric Association; Canadian Network for Mood and Anxiety
Treatments (CANMAT): Clinical guidelines for the treatment of depressive
disorders. Can J Psychiatry 2001, 46(Suppl 1):1S–91S.6. Thase ME, Larsen KG, Kennedy SH: Assessing the ‘true’ effect of active
antidepressant therapy v. placebo in major depressive disorder: use of a
mixture model. Br J Psychiatry 2011, 199(6):501–507.
7. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C,
Jones KL, Mitchell AA: Selective serotonin-reuptake inhibitors and risk of
persistent pulmonary hypertension of the newborn. N Engl J Med 2006,
354(6):579–587.
8. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, Walker M:
Selective serotonin reuptake inhibitors and adverse pregnancy
outcomes. Am J Obstet Gynecol 2006, 194(4):961–966.
9. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A,
Hoyme HE: Follow-up of children of depressed mothers exposed or
not exposed to antidepressant drugs during pregnancy. J Pediatr 2003,
142(4):402–408.
10. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL: Birth outcomes in
pregnant women taking fluoxetine. N Engl J Med 1996, 335(14):1010–1015.
11. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM: Birth outcomes
following prenatal exposure to fluoxetine. Biol Psychiatry 2000, 48(10):996–1000.
12. Costei AM, Kozer E, Ho T, Ito S, Koren G: Perinatal outcome following
third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002,
156(11):1129–1132.
13. Ericson A, Kallen B, Wiholm B: Delivery outcome after the use of antidepressants
in early pregnancy. Eur J Clin Pharmacol 1999, 55(7):503–508.
14. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M,
Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G:
Pregnancy outcome following maternal use of the new selective serotonin
reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998,
279(8):609–610.
15. Laine K, Heikkinen T, Ekblad U, Kero P: Effects of exposure to selective
serotonin reuptake inhibitors during pregnancy on serotonergic
symptoms in newborns and cord blood monoamine and prolactin
concentrations. Arch Gen Psychiatry 2003, 60(7):720–726.
16. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G: Neonatal abstinence
syndrome after in utero exposure to selective serotonin reuptake inhibitors
in term infants. Arch Pediatr Adolesc Med 2006, 160(2):173–176.
17. Nordeng H, Lindemann R, Perminov KV, Reikvam A: Neonatal withdrawal
syndrome after in utero exposure to selective serotonin reuptake
inhibitors. Acta Paediatr 2001, 90(3):288–291.
18. Oberlander TF, Eckstein Grunau R, Fitzgerald C, Ellwood AL, Misri S, Rurak D,
Riggs KW: Prolonged prenatal psychotropic medication exposure alters
neonatal acute pain response. Pediatr Res 2002, 51(4):443–453.
19. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S,
Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, Gardner A,
Horn M, Koren G: Pregnancy outcome following first-trimester exposure
to fluoxetine (Prozac). JAMA 1993, 269(17):2246–2248.
20. Simon GE, Cunningham ML, Davis RL: Outcomes of prenatal
antidepressant exposure. Am J Psychiatry 2002, 159(12):2055–2061.
21. Stiskal JA, Kulin N, Koren G, Ho T, Ito S: Neonatal paroxetine withdrawal
syndrome. Arch Dis Child Fetal Neonatal Ed 2001, 84(2):F134–F135.
22. Mulder EJ, Ververs FF, de Heus R, Visser GH: Selective serotonin reuptake
inhibitors affect neurobehavioral development in the human fetus.
Neuropsychopharmacology 2011, 36(10):1961–1971.
23. Fitzgerald PB, Brown TL, Marston NA, Daskalakis ZJ, De Castella A, Kulkarni J:
Transcranial magnetic stimulation in the treatment of depression: a
double-blind, placebo-controlled trial. Arch Gen Psychiatry 2003,
60(10):1002–1008.
24. George MS, Ketter TA, Post RM: Prefrontal cortex dysfunction in clinical
depression. Depression 1994, 2(2):59–72.
25. Speer AM, Kimbrell TA, Wassermann EM, Repella JD, Willis MW,
Herscovitch P, Post RM: Opposite effects of high and low frequency
rTMS on regional brain activity in depressed patients. Biol Psychiatry
2000, 48(12):1133–1141.
26. Ardolino G, Bossi B, Barbieri S, Priori A: Non-synaptic mechanisms underlie
the after-effects of cathodal transcutaneous direct current stimulation of
the human brain. J Physiol 2005, 568(2):653–663.
27. Miranda PC, Lomarev M, Hallett M: Modeling the current distribution
during transcranial direct current stimulation. Clin Neurophysiol 2006,
117(7):1623–1629.
28. Merzagora AC, Foffani G, Panyavin I, Mordillo-Mateos L, Aguilar J, Onaral B,
Oliviero A: Prefrontal hemodynamic changes produced by anodal direct
current stimulation. Neuroimage 2010, 49(3):2304–2310.
Vigod et al. Trials 2014, 15:366 Page 11 of 11
http://www.trialsjournal.com/content/15/1/36629. Kalu UG, Sexton CE, Loo CK, Ebmeier KP: Transcranial direct current
stimulation in the treatment of major depression: a meta-analysis.
Psychol Med 2012, 42(9):1791–1800.
30. Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P: Transcranial
direct current stimulation for depression: 3-week, randomised,
sham-controlled trial. Br J Psychiatry 2012, 200(1):52–59.
31. Boggio PS, Castro LO, Savagim EA, Braite R, Cruz VC, Rocha RR, Rigonatti SP,
Silva MT, Fregni F: Enhancement of non-dominant hand motor function
by anodal transcranial direct current stimulation. Neurosci Lett 2006,
404(1–2):232–236.
32. Fregni F, Boggio PS, Lima MC, Ferreira MJ, Wagner T, Rigonatti SP, Castro
AW, Souza DR, Riberto M, Freedman SD, Nitsche MA, Pascual-Leone A:
A sham-controlled, phase II trial of transcranial direct current stimulation
for the treatment of central pain in traumatic spinal cord injury.
Pain 2006, 122(1–2):197–209.
33. Fregni F, Boggio PS, Mansur CG, Wagner T, Ferreira MJ, Lima MC, Rigonatti SP,
Marcolin MA, Freedman SD, Nitsche MA, Pascual-Leone A: Transcranial
direct current stimulation of the unaffected hemisphere in stroke patients.
Neuroreport 2005, 16(14):1551–1555.
34. Fregni F, Boggio PS, Nitsche M, Bermpohl F, Antal A, Feredoes E, Marcolin MA,
Rigonatti SP, Silva MT, Paulus W, Pascual-Leone A: Anodal transcranial direct
current stimulation of prefrontal cortex enhances working memory.
Exp Brain Res 2005, 166(1):23–30.
35. Fregni F, Boggio PS, Nitsche MA, Marcolin MA, Rigonatti SP, Pascual-Leone A:
Treatment of major depression with transcranial direct current stimulation.
Bipolar Disord 2006, 8(2):203–204.
36. Lang N, Nitsche MA, Paulus W, Rothwell JC, Lemon RN: Effects of transcranial
direct current stimulation over the human motor cortex on corticospinal
and transcallosal excitability. Exp Brain Res 2004, 156(4):439–443.
37. Nitsche MA, Liebetanz D, Lang N, Antal A, Tergau F, Paulus W: Safety
criteria for transcranial direct current stimulation (tDCS) in humans.
Clin Neurophysiol 2003, 114(11):2220–2222. author reply 2222–3.
38. Nitsche MA, Boggio PS, Fregni F, Pascual-Leone A: Treatment of depression
with transcranial direct current stimulation (tDCS): a review. Exp Neurol
2009, 219(1):14–19.
39. Poreisz C, Boros K, Antal A, Paulus W: Safety aspects of transcranial direct
current stimulation concerning healthy subjects and patients. Brain Res Bull
2007, 72(4–6):208–214.
40. Raimundo RJ, Uribe CE, Brasil-Neto JP: Lack of clinically detectable acute
changes on autonomic or thermoregulatory functions in healthy subjects
after transcranial direct current stimulation (tDCS). Brain Stimul 2012,
5(3):196–200.
41. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E,
Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric
Interview (M.I.N.I.): the development and validation of a structured
diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry
1998, 59(Suppl 20):22–33.
42. Ellish NJ, Saboda K, O’Connor J, Nasca PC, Stanek EJ, Boyle C: A prospective
study of early pregnancy loss. Hum Reprod 1996, 11(2):406–412.
43. Kelly RH, Russo J, Holt VL, Danielsen BH, Zatzick DF, Walker E, Katon W:
Psychiatric and substance use disorders as risk factors for low birth
weight and preterm delivery. Obstet Gynecol 2002, 100(2):297–304.
44. Patel SR, Wisner KL: Decision making for depression treatment during
pregnancy and the postpartum period. Depress Anxiety 2011, 28(7):589–595.
45. Blumberger DM, Tran LC, Fitzgerald PB, Hoy KE, Daskalakis ZJ: A
randomized double-blind sham-controlled study of transcranial direct
current stimulation for treatment-resistant major depression. Front
Psychiatry 2012, 3:74.
46. Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Vieira GP,
Bueno VF, Goulart AC, Boggio PS, Lotufo PA, Bensenor IM, Fregni F:
Sertraline vs. ELectrical Current Therapy for Treating Depression Clinical
Trial–SELECT TDCS: design, rationale and objectives. Contemp Clin Trials
2011, 32(1):90–98.
47. Brunoni AR, Vanderhasselt MA, Boggio PS, Fregni F, Dantas EM, Mill JG,
Lotufo PA, Benseñor IM: Polarity- and valence-dependent effects of
prefrontal transcranial direct current stimulation on heart rate variability
and salivary cortisol. Psychoneuroendocrinology 2013, 38(1):58–66.
48. Herwig U, Padberg F, Unger J, Spitzer M, Schönfeldt-Lecuona C: Transcranial
magnetic stimulation in therapy studies: examination of the reliability of
‘standard’ coil positioning by neuronavigation. Biol Psychiatry 2001, 50(1):58–61.49. Vanderkooy JD, Kennedy SH, Bagby RM: Antidepressant side effects in
depression patients treated in a naturalistic setting: a study of bupropion,
moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002,
47(2):174–180.
50. Demissie K, Joseph KS, Dzakpasu S: Perinatal Health Indicators for Canada: A
Resource Manual. Ottawa, ON: Health Canada; 2000.
51. Bates JE, Freeland CA, Lounsbury ML: Measurement of infant difficultness.
Child Dev 1979, 50(3):794–803.
52. Bricker D, Squires J: Ages and Stages Questionnaire. 3rd edition. Baltimore,
MD: Brookes Publishing; 2010.
53. Schonhaut L, Armijo I, Schönstedt M, Alvarez J, Cordero M: Validity of the
ages and stages questionnaires in term and preterm infants. Pediatrics
2013, 131(5):e1468–e1474.
54. Hermens ML, Adèr HJ, van Hout HP, Terluin B, van Dyck R, de Haan M:
Administering the MADRS by telephone or face-to-face: a validity study.
Ann Gen Psychiatry 2006, 5:3.
55. Kjaergaard M, Arfwedson Wang CE, Waterloo K, Jorde R: A study of the
psychometric properties of the Beck depression Inventory-II, the
montgomery and Asberg depression rating scale, and the hospital
anxiety and depression scale in a sample from a healthy population.
Scand J Psychol 2014, 55(1):83–89.
56. Gibson J, McKenzie-McHarg K, Shakespeare J, Price J, Gray R: A systematic
review of studies validating the Edinburgh Postnatal Depression Scale
in antepartum and postpartum women. Acta Psychiatr Scand 2009,
119(5):350–364.
57. Boyd RC, Le HN, Somberg R: Review of screening instruments for
postpartum depression. Arch Womens Ment Health 2005, 8(3):141–153.
58. Eberhard-Gran M, Eskild A, Tambs K, Opjordsmoen S, Samuelsen SO:
Review of validation studies of the Edinburgh postnatal depression scale.
Acta Psychiatr Scand 2001, 104(4):243–249.
59. DiPietro JA, Ghera MM, Costigan K, Hawkins M: Measuring the ups and downs
of pregnancy stress. J Psychosom Obstet Gynaecol 2004, 25(3–4):189–201.
60. Dennis CL, Coghlan M, Vigod S: Can we identify mothers at-risk for postpartum
anxiety in the immediate postpartum period using the State-Trait
Anxiety Inventory? J Affect Disord 2013, 150:1217–1220.
61. Hertzog MA: Considerations in determining sample size for pilot studies.
Res Nurs Health 2008, 31(2):180–191.
62. Walton GD, Ross LE, Stewart DE, Grigoriadis S, Dennis CL, Vigod S: Decisional
conflict among women considering antidepressant medication use in
pregnancy. Arch Womens Ment Health 2014, doi:10.1007/s00737-014-0448-1.
63. Dowswell T, Bedwell C, Lavender T, Neilson JP: Transcutaneous electrical
nerve stimulation (TENS) for pain relief in labour. Cochrane Database Syst Rev
2009, 2:CD007214.
doi:10.1186/1745-6215-15-366
Cite this article as: Vigod et al.: Transcranial direct current stimulation
(tDCS) for treatment of major depression during pregnancy: study
protocol for a pilot randomized controlled trial. Trials 2014 15:366.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
